Combinations of Psychoplastogens and DYRK1A Inhibitors

Abstract

Researchers at the University of California, Davis have developed a class of compounds intended for the treatment of neurodegenerative diseases such as Alzheimer's by inhibiting DYRK1A kinase and modulating 5-HT2Rs.

Full Description

This technology consists of compounds functioning as both inhibitors of the kinase DYRK1A and psychoplastogenic modulators of serotonin 2 receptors (5-HT2Rs). These compounds are considered promising for developing therapeutics to treat neurodegenerative diseases like Alzheimer's. DYRK1A is known to phosphorylate amyloid precursor protein and tau protein, which play a role in the pathophysiology of Alzheimer's, Down Syndrome, and related diseases. Inhibiting DYRK1A activity, along with promoting cortical neuron growth through 5-HT2 modulation has potential for rescuing the cortical atrophy and cognitive impairment observed in conditions like Alzheimer's and Down syndrome.

Applications

• Treatment of neurodegenerative diseases, particularly Alzheimer's disease. 
• Treatment of Down syndrome. 
• Potential use in the development of a new class of therapeutics for neurodegenerative disorders.

Features/Benefits

• Inhibits DYRK1A activity, involved in the development of neurodegenerative diseases and Down syndrome. 
• Blocks tau hyperphosphorylation. 
• Promotes cortical neuron growth. 
• Potential synergism between DYRK1A inhibition and 5-HT2Rs for Alzheimer's prevention/treatment. 
• Development and progression of treatments for Alzheimer's and related neurodegenerative diseases.

Patent Status

Patent Pending